See today's BioWorld AsiaSee today's BioWorld
To read the full story, subscribe or sign in.

Qyuns’ QX-002N hits endpoints in ankylosing spondylitis trial

Feb. 25, 2025
By Tamra Sami
Qyuns Therapeutics Co. Ltd.’s monoclonal antibody targeting IL-17A, QX-002N, met both primary and secondary endpoints in a phase III trial in ankylosing spondylitis.
BioWorld BioWorld Asia Clinical Immune Inflammatory Musculoskeletal Monoclonal antibody Asia-Pacific China NMPA